(MAIA) MAIA Biotechnology, Inc. Business Model Canvas Research

External scientists help validate MAIA Biotechnology, Inc.'s THIO telomere-targeting and immune-stimulating science, which matters as the Company moved its 2025 clinical work forward. Investigator-led studies also support translational research and publication of clinical findings, giving regulators and partners more proof that the biology holds up outside MAIA Biotechnology, Inc.'s own lab.

• Independent validation of THIO
• Supports clinical publications
• Boosts regulator and partner trust

MAIA Biotechnology, Inc. depends on FDA review and local ethics boards to approve trial plans, patient consent, and data rules. In oncology, where MAIA’s clinical work can hinge on small Phase 1/2 cohorts and tight protocol control, close coordination helps reduce delay risk and compliance rework.

• FDA and IRB approval gate each study step
• Ethics review protects patients and data
• Alignment lowers trial delay risk

MAIA Biotechnology, Inc. runs filings, protocol amendments, and trial records for its clinical program, while tracking timelines, safety reports, and GCP compliance. In U.S. trials, serious unexpected adverse events can require FDA reporting within 7 calendar days, so tight trial control is critical to keep the lead program moving.

• Keep filings current
• Track safety fast
• Protect trial continuity

MAIA Biotechnology, Inc. uses biomarker and clinical data analysis to track response patterns in its THIO program and to see which patient groups may benefit most. That evidence can shape the next study design and support partnering talks with clearer patient selection and endpoint strategy.

• Finds response patterns from trial data
• Helps define likely beneficiary patients
• Supports future study and partner talks

MAIA Biotechnology, Inc.’s oncology management team is a key resource because a high-risk drug program needs tight execution across science, clinical ops, finance, and business development. In biotech, where one delayed trial or funding gap can change the outlook fast, leadership quality is a real competitive edge.

• Coordinates trial execution and capital use
• Aligns science with business goals
• Improves speed, control, and decision quality

MAIA Biotechnology, Inc. depends on public-market capital because it is still pre-revenue, so equity funding keeps its research runway alive until product sales start. That makes access to the market a core resource: if financing tightens, trial work slows and the company’s development window shortens.

• Public equity funds R&D and trials
• Access matters before first sales
• Runway length drives development pace

THIO is designed to pair with existing immunotherapy and other cancer regimens, not replace them. In MAIA Biotechnology, Inc. studies, the asset has been tested in advanced non-small cell lung cancer, where 5-year survival remains low at roughly 30% in stage IIIA and under 10% in stage IV, so even modest combo gains can matter commercially.

• Built as a partner drug
• Combo use may beat monotherapy
• Wider use can expand revenue potential

MAIA Biotechnology, Inc. is not just a one-tumor story: its lead program targets NSCLC, but the same platform can support broader solid-tumor use if the data hold up. That matters because a label beyond 1 indication can lift peak sales and valuation, and MAIA’s 2025 filing still shows a development-stage company with no product revenue, so upside depends on clinical expansion.

• Lead focus: NSCLC
• Platform can reach more tumors
• 1 positive readout can expand label
• Broader use can raise long-term value

MAIA Biotechnology, Inc. likely keeps a steady dialogue with licensing and development partners, because co-development or out-licensing depends on clear clinical proof and a clean data package. Strong trial readouts matter: in oncology, partners usually want enough efficacy and safety data to justify moving from talks to term sheets.

• Keep partners updated on key readouts.
• Use data to support licensing talks.
• Share safety and efficacy evidence fast.

MAIA Biotechnology, Inc., as a public biotech, must keep shareholders updated through earnings calls, SEC filings, and deal or trial news. This matters because biotech financing often depends on investor trust, and regular disclosure helps preserve access to capital.

• Quarterly and annual SEC filings
• Earnings calls and Q&A
• Trial and financing updates
• Supports transparency and capital access

For a company like MAIA Biotechnology, Inc., this investor link is not optional; it is part of staying funded while programs move forward.

MAIA Biotechnology, Inc. uses peer-reviewed papers and corporate updates to show trial progress and build scientific credibility; this matters because the Company reported no product revenue in its latest filings. With no sales base, every data release and publication helps keep investors and partners informed about THIO and other pipeline milestones.

• Peer review builds trust
• Updates show trial progress
• No product revenue raises disclosure value

MAIA Biotechnology, Inc. uses SEC filings and investor outreach to tell capital markets how its lead oncology programs are progressing, what risks remain, and how much cash it has to fund work; as a clinical-stage company with no product revenue, these updates matter most for valuation and access to financing.

• 10-K, 10-Q, 8-K, proxy
• Guidance on trials and cash use
• Shapes investor demand and pricing

Strategic pharmaceutical partners may want access to MAIA Biotechnology, Inc.’s THIO or related oncology rights to add a differentiated pipeline asset. These partners matter because they can fund late-stage work, bring trial ops support, and open commercialization paths; a positive readout can lift partnering leverage and deal value.

• Access to THIO oncology rights
• Funding and development support
• Commercialization pathway access
• Stronger terms after positive data

MAIA Biotechnology, Inc. serves capital markets investors who fund its long, pre-revenue drug development path and price the stock around trial milestones, not sales. As a public clinical-stage Company Name, its equity story depends on data readouts, regulatory steps, and capital raises that can dilute shareholders.

• Finances long R&D cycles
• Tracks milestone-based value creation
• Accepts higher dilution risk

MAIA Biotechnology, Inc. uses general and administrative costs for public-company overhead: finance, legal, HR, and SEC and exchange reporting. This line also covers management and corporate ops, so it tends to rise with filing cadence and board support needs.

• Finance, legal, HR support
• SEC and exchange compliance
• Corporate management costs

IP, regulatory, and legal costs are a permanent biotech expense for MAIA Biotechnology, Inc.: patent upkeep, FDA filings, and counsel fees keep THIO protected and development on track. In the U.S., patent maintenance alone can run through 3 fee windows at 3.5, 7.5, and 11.5 years, so these are not one-time costs.

• Protects MAIA Biotechnology, Inc.'s core asset

• Covers filings, counsel, and compliance

• Non-optional cost in biotech

MAIA Biotechnology, Inc. is still pre-revenue in its 2025 reporting, so research collaboration payments are a future funding path rather than a current income base. Joint deals can bring fee-based cash for named studies or strategic programs, and they can also signal outside validation of the asset to partners and investors.

• 2025 revenue: $0
• Fees can fund specific studies
• Co-development can validate the asset

THIO remains pre-commercial, so future product sales still depend on late-stage success and FDA approval. If approved, direct THIO sales could become MAIA Biotechnology, Inc.'s largest recurring revenue stream, but today there is no THIO product revenue.

• Approval is the key trigger
• Direct sales would drive revenue
• No current THIO sales yet